The biggest obstacles that still stand in the way of universal AAV utilization are the difficulties of purifying AAVs and the low viral amounts obtained.
A more refined, efficient and economical method for producing of adeno-associated viral vectors (AAVs) for gene therapy has presented an improved revision of current preparation protocol.
Using iodixanol purification, this new protocol aims to overcome these obstacles. By eliminating contaminants, this method of purification improves AAV purity, lowers inflammation, and improves viral transduction in vivo.
This could make it much easier to develop gene-based medicine by providing access to inexpensive and pure AAV preparations in the future.